Profile data is unavailable for this security.
About the company
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
- Revenue in EUR (TTM)-14.04m
- Net income in EUR-51.64m
- Incorporated2003
- Employees103.00
- LocationNanobiotix SA60 rue de WattigniesPARIS 75012FranceFRA
- Phone+33 140260470
- Fax+33 140260444
- Websitehttps://www.nanobiotix.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valneva SE | 174.70m | 16.80m | 798.04m | 700.00 | -- | -- | -- | 4.57 | -0.375 | -0.375 | -- | -- | -- | -- | -- | 251,366.90 | -- | -14.46 | -- | -23.62 | 9.62 | 34.12 | 9.62 | -34.54 | -- | 1.84 | -- | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Basilea Pharmaceutica AG Allschwil | 255.13m | 44.18m | 798.49m | 189.00 | 18.52 | 5.25 | 17.29 | 3.13 | 2.95 | 2.95 | 16.98 | 10.41 | 0.861 | 1.48 | 20.78 | 1,229,524.00 | 14.91 | 11.57 | 18.09 | 17.51 | 83.08 | 82.84 | 17.32 | 14.94 | 4.68 | 24.70 | 0.3709 | -- | 11.43 | 12.73 | -48.14 | -- | 4.79 | -- |
| Gubra A/S | 352.95m | 226.29m | 842.57m | 269.00 | -- | 5.49 | -- | 2.39 | -4.42 | -4.42 | 161.57 | 70.16 | 2.73 | -- | 62.03 | 9,802,271.00 | 174.97 | 65.69 | 191.26 | 79.14 | 4.11 | 87.02 | 64.11 | 47.21 | -- | 20.13 | 0.0857 | -- | 892.25 | 72.57 | 4,731.94 | 166.01 | 21.62 | -- |
| Oxford BioMedica plc | 173.46m | -42.52m | 894.35m | 900.00 | -- | 20.92 | -- | 5.16 | -0.3539 | -0.3539 | 1.46 | 0.3084 | 0.6556 | 5.25 | 4.25 | 175,626.00 | -16.95 | -20.23 | -23.87 | -25.48 | 44.12 | 49.36 | -25.85 | -45.03 | 1.67 | -4.81 | 0.7631 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
| Evotec SE | 756.33m | -158.98m | 1.01bn | 4.79k | -- | 1.26 | -- | 1.34 | -0.8955 | -0.8955 | 4.26 | 4.50 | 0.4019 | 20.15 | 5.17 | 156,687.00 | -8.45 | -2.40 | -10.41 | -2.87 | 10.82 | 21.49 | -21.02 | -6.78 | 2.03 | -2.54 | 0.3772 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Inventiva SA | 13.61m | -311.07m | 1.10bn | 84.00 | -- | -- | -- | 81.03 | -3.62 | -3.62 | 0.1543 | -0.064 | 0.1247 | -- | 2.35 | 124,871.60 | -284.55 | -80.43 | -555.93 | -122.98 | -- | -- | -2,282.71 | -989.96 | -- | -0.5041 | 1.18 | -- | -47.37 | 5.62 | -66.82 | -- | 19.61 | -- |
| Idorsia Ltd | 255.27m | -129.49m | 1.14bn | 938.00 | -- | -- | -- | 4.45 | -0.6593 | -0.6593 | 1.06 | -4.88 | 0.4807 | 0.3793 | 796.27 | -- | -24.38 | -48.63 | -53.54 | -61.12 | 86.49 | -- | -50.72 | -526.39 | 0.8345 | -6.02 | 31.03 | -- | -26.17 | 36.41 | 11.47 | -- | -1.08 | -- |
| Kuros Biosciences AG | 97.17m | -5.18m | 1.18bn | 122.00 | -- | 17.40 | -- | 12.15 | -0.1236 | -0.1369 | 2.29 | 1.58 | 1.16 | 1.75 | 7.11 | 725,422.60 | -6.18 | -10.85 | -7.79 | -12.28 | 83.57 | 84.11 | -5.33 | -31.80 | 1.74 | -0.4702 | 0.0655 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| Nanobiotix SA | -14.04m | -51.64m | 1.31bn | 103.00 | -- | -- | -- | -- | -1.09 | -1.09 | -0.2962 | -1.43 | -0.213 | -- | -- | -130,037.00 | -78.34 | -54.39 | -839.67 | -90.60 | -- | -- | -- | -1,326.20 | -- | -7.32 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
| Galapagos NV | 1.11bn | 319.49m | 1.91bn | 558.00 | 5.96 | 0.5889 | -- | 1.71 | 4.85 | 4.87 | 16.88 | 49.10 | 0.2949 | 0.8071 | 32.63 | -- | 8.47 | 0.5107 | 9.06 | 0.5661 | 97.33 | -- | 28.72 | 4.80 | 20.00 | -- | 0.0021 | -- | 303.50 | 15.97 | 25,021.37 | -- | -31.41 | -- |
Data as of Mar 03 2026. Currency figures normalised to Nanobiotix SA's reporting currency: Euro EUR
25.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 02 Apr 2025 | 5.84m | 12.08% |
| Baillie Gifford & Co.as of 19 Nov 2024 | 2.36m | 4.89% |
| Goldman Sachs International (Invt Mgmt)as of 26 Jan 2026 | 2.23m | 4.61% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 516.97k | 1.07% |
| CPR Asset Management SAas of 31 Dec 2025 | 448.85k | 0.93% |
| Oddo BHF Asset Management SASas of 30 Jan 2026 | 376.77k | 0.78% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 282.49k | 0.58% |
| Medical Strategy GmbHas of 30 Dec 2025 | 156.00k | 0.32% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 113.44k | 0.23% |
| Soci�t� G�n�rale Investment Solutions (France)as of 07 Jul 2025 | 110.00k | 0.23% |
More ▼
Data from 14 Nov 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
